{"id":923,"date":"2024-01-22T13:24:40","date_gmt":"2024-02-01T14:24:29","guid":{"rendered":"https:\/\/devm.kyowakirininternational.com\/?page_id=923"},"modified":"2025-08-01T09:38:10","modified_gmt":"2025-08-01T08:38:10","slug":"news","status":"publish","type":"page","link":"https:\/\/kyowakirininternational.com\/dach-de\/news\/","title":{"rendered":"News"},"content":{"rendered":"\n[et_pb_section fb_built=”1″ admin_label=”Section” _builder_version=”4.24.3″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”25px||-30px||false|false” global_module=”692″ saved_tabs=”all” locked=”off” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.26.1″ _module_preset=”default” background_color=”#e5e5e5″ width=”100%” max_width=”100%” custom_margin=”-55px||||false|false” custom_margin_tablet=”” custom_margin_phone=”” custom_margin_last_edited=”on|desktop” custom_padding=”0px|0px|0px|0px|false|false” global_colors_info=”{}”][et_pb_column type=”1_3″ admin_label=”Column” _builder_version=”4.24.3″ _module_preset=”default” custom_padding=”25px|||5px|false|false” global_colors_info=”{}”][et_pb_text content_tablet=” <\/p>\n

Healthcare Professionals Hub<\/span><\/a><\/p>\n

” content_phone=”<\/p>\n

Healthcare Professionals Hub<\/span><\/a><\/p>\n

” content_last_edited=”on|phone” admin_label=”Text” _builder_version=”4.27.4″ _module_preset=”default” text_font=”|700|||||||” text_text_color=”#ea5504″ text_orientation=”center” custom_margin=”||||false|false” custom_margin_tablet=”” custom_margin_phone=”||||false|false” custom_margin_last_edited=”on|phone” custom_padding=”||||false|false” link_option_url_new_window=”on” text_text_color_tablet=”” text_text_color_phone=”” text_text_color_last_edited=”on|phone” global_colors_info=”{}”]

Bereich f\u00fcr Medizinische Fachkr\u00e4fte<\/span><\/a><\/p>[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ admin_label=”Column” _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_3″ admin_label=”Column” _builder_version=”4.24.0″ _module_preset=”default” background_color_phone=”RGBA(255,255,255,0)” background_last_edited=”on|phone” background_enable_color_phone=”on” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” text_font=”|700|||||||” text_text_color=”#FFFFFF” background_color=”#ea5504″ width=”100%” module_alignment=”center” custom_margin=”||||false|false” custom_margin_tablet=”” custom_margin_phone=”||||false|false” custom_margin_last_edited=”on|desktop” custom_padding=”10px||||false|false” link_option_url=”https:\/\/kyowakirininternational.com\/global-reporting\/” link_option_url_new_window=”on” border_color_all=”#FFFFFF” global_colors_info=”{}”]

Unerw\u00fcnschtes Ereignis melden \"\"<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” z_index=”500″ width=”100%” max_width=”100%” min_height=”100px” height=”100px” overflow-x=”visible” overflow-y=”visible” custom_margin=”||||false|false” custom_padding=”|||25px|false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_menu menu_id=”37″ active_link_color=”#ea5504″ dropdown_menu_bg_color=”#5d6164″ dropdown_menu_line_color=”#ff3300″ dropdown_menu_text_color=”#000000″ dropdown_menu_active_link_color=”#ff3300″ mobile_menu_bg_color=”#b4c0c1″ mobile_menu_text_color=”#000000″ logo=”https:\/\/kyowakirininternational.com\/dach-de\/wp-content\/uploads\/sites\/17\/2024\/01\/KyowaKirin_BrandLogo_colorv2-PhotoRoom-1-1024×216.png” logo_url=”https:\/\/kyowakirininternational.com\/dach-de\/” logo_width=”100%” logo_max_width=”17%” show_search_icon=”on” search_icon_color=”#ea5504″ menu_icon_color=”#ea5504″ logo_max_width_tablet=”35%” logo_max_width_phone=”76%” logo_max_width_last_edited=”on|phone” show_search_icon_tablet=”on” show_search_icon_phone=”on” show_search_icon_last_edited=”on|phone” search_icon_color_tablet=”#ea5504″ search_icon_color_phone=”#ea5504″ search_icon_color_last_edited=”on|phone” _builder_version=”4.25.1″ _module_preset=”default” menu_font=”|600|||||||” menu_text_color=”#5d6164″ menu_font_size=”17px” background_color=”RGBA(255,255,255,0)” custom_css_free_form=”.et_pb_menu__icon.et_pb_menu__search-button {||padding: 2% 2% 2% 1%;||||}” global_colors_info=”{}”][\/et_pb_menu][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” width=”90%” max_width=”100%” custom_margin=”-25px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][lwp_divi_breadcrumbs home_text=”Homepage” font_icon=”5||divi||400″ link_color=”#5d6164″ separator_color=”#e95505″ current_text_color=”#e95505″ _builder_version=”4.27.4″ _module_preset=”default” module_text_align=”left” background_color=”RGBA(255,255,255,0)” text_orientation=”left” animation_style=”fade” global_module=”1047″ global_colors_info=”{}”][\/lwp_divi_breadcrumbs][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” background_color=”#5d6164″ height=”50px” height_tablet=”100px” height_phone=”140px” height_last_edited=”on|phone” custom_margin=”||||false|false” custom_padding=”||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.25.1″ _module_preset=”default” custom_margin=”-40px||||false|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_menu menu_id=”39″ menu_style=”centered” active_link_color=”#ea5504″ dropdown_menu_line_color=”#ea5504″ dropdown_menu_active_link_color=”#ea5504″ mobile_menu_bg_color=”#b4c0c1″ mobile_menu_text_color=”#000000″ menu_icon_color=”#ea5504″ _builder_version=”4.25.1″ _module_preset=”default” menu_text_color=”#FFFFFF” menu_font_size=”15px” background_color=”RGBA(255,255,255,0)” global_colors_info=”{}”][\/et_pb_menu][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ next_background_color=”#ffffff” module_id=”announcements” _builder_version=”4.24.2″ _module_preset=”default” background_color=”#ea5504″ bottom_divider_style=”slant2″ bottom_divider_height=”42px” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_font=”|700|||||||” header_text_color=”#ffffff” global_colors_info=”{}”]

News<\/h1>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ next_background_color=”#e5e5e5″ module_id=”news” _builder_version=”4.24.2″ _module_preset=”default” bottom_divider_style=”slant2″ bottom_divider_height=”52px” bottom_divider_flip=”horizontal” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_color=”#ea5504″ global_colors_info=”{}”]

Aktuelle News <\/strong><\/h2>\n

Diese Seite ist nicht f\u00fcr die allgemeine \u00d6ffentlichkeit bestimmt. Die von Kyowa Kirin herausgegebenen Pressemitteilungen sollen Fachmedien und Investoren ausgewogen \u00fcber Sachverhalte und Entwicklungen informieren, die im Zusammenhang mit der Gesch\u00e4ftst\u00e4tigkeit des Unternehmens stehen. \u00a0Sie k\u00f6nnen zwar Informationen zu pharmazeutischen Produkten enthalten (einschlie\u00dflich Produkten, die sich noch in der Entwicklung befinden), verfolgen in diesen F\u00e4llen jedoch nicht werbliche, verkaufsf\u00f6rdernde oder medizinisch beratende Zwecke.<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.26.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.26.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia<\/strong>
Download<\/a>
1 October 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.26.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.26.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin to Present New Research Spotlighting Global Efforts to Advance Science and Patient Care in X-linked Hypophosphatemia at ASBMR Annual Meeting<\/strong>
Download<\/a>
26 September 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)<\/strong>
Download<\/a>
10 September 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin International and NewBridge Pharmaceuticals enter into agreement to improve access to medicines for rare disease patients across Middle East and North Africa<\/strong>
Download<\/a>
07 August 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.26.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Polish Ministry of Health approves reimbursement of POTELIGEO\u00ae (mogamulizumab) for adults living with mycosis fungoides or S\u00e9zary syndrome.<\/span><\/strong>
Download<\/a>
31 July 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

NICE enables access to first treatment that targets the underlying pathophysiology of rare disease X-linked hypophosphataemia (XLH) in adults.<\/span><\/strong>
Download<\/a>
14 May 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

CTCL Global Care Collaborative Pioneers Consensus for Improving Diagnosis and Care in Cutaneous T-Cell Lymphoma (CTCL).<\/span><\/strong>
Download<\/a>
14 May 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

First Interim Analysis of PROSPER Study Details Patient-Reported Symptom Burden of MF and SS.<\/span><\/strong>
Download<\/a>
15 April 2024<\/span><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases.<\/strong>
Download<\/a>
24 January 2024<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

New Post Hoc Analysis from MAVORIC Trial Sheds Light on the Burden of Cutaneous T-Cell Lymphoma on Health-Related Quality of Life.<\/strong>
Download<\/a>
11 December 2023<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Responds to NICE\u2019s Publication of Appraisal Consultation Document for CRYSVITA\u00ae (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults.<\/strong>
Download<\/a>
29 November 2023<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin demonstrates commitment to real-world evidence for POTELIGEO\u00ae (mogamulizumab) at EORTC 2023.<\/strong>
Download<\/a>
21 September 2023<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Gr\u00fcnenthal and Kyowa Kirin International Announce Successful Completion of Deal to Enter Joint Venture Collaboration.<\/strong>
Download<\/a>
2 August 2023<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Scottish Medicines Consortium (SMC) Enables Access to First Treatment Tackling the Underlying Cause of X-Linked Hypophosphataemia (XLH) in Adults.<\/strong>
Download<\/a>
13 February 2023<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Gr\u00fcnenthal and Kyowa Kirin International announce Joint Venture Collaboration for established medicines portfolio.<\/strong>
24 November 2022
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Appoints Abdul Mullick, President, Kyowa Kirin International, to New Global Role as Vice Chief International Business Officer; Jeremy Morgan appointed President, Kyowa Kirin International<\/strong>
08 November 2022
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin receives European Commission Approval for Use of CRYSVITA\u00ae\u25bc(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).<\/strong>
18 August 2022
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA\u00ae \u25bc(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO).<\/strong>
28 June 2022
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

New Real World Evidence Underlines Benefits of POTELIGEO\u00ae\u25bc (mogamulizumab) Treatment for Cutaneous T-cell Lymphoma (CTCL) Patients.<\/strong>
14 October 2021
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Long-term CRYSVITA\u00ae \u25bc (burosumab) treatment reduces the burden of disease in adults with X-Linked Hypophosphataemia (XLH), a rare genetic metabolic bone disease.<\/strong>
24 September 2021
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Announces EU Approval for the Self-administration of CRYSVITA\u00ae \u25bc (burosumab) to Treat X-Linked Hypophosphataemia (XLH)<\/strong>
19 July 2021
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin welcomes the decision that the National Institute for Health and Care Excellence will revisit their appraisal <\/strong>of the innovative systemic treatment, POTELIGEO\u00ae (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma.<\/strong>
11 June 2021
Download<\/a><\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

New Data Analysis Shows Link between Blood Involvement and Response to Treatment in Cutaneous T-cell Lymphoma (CTCL) Patients.<\/strong>
Download<\/a>
11 June 2021<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Receives Positive CHMP Opinion for the Self-administration of CRYSVITA\u00ae \u25bc (burosumab) to Treat X-Linked Hypophosphataemia (XLH), a Rare Metabolic Bone Disorder.<\/strong>
Download<\/a>
07 May 2021<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin responds to the National Institute for Health and Care Excellence (NICE) decision to not provide people living with certain rare blood cancers access to POTELIGEO\u00ae (mogamulizumab).<\/strong>
Download<\/a>
04 March 2021<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_icon font_icon=”||fa||900″ icon_color=”#ea5504″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_icon][\/et_pb_column][et_pb_column type=”3_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font_size=”16px” global_colors_info=”{}”]

Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA\u00ae (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH).<\/strong>
Download<\/a>
24 July 2020<\/p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ next_background_color=”#FFFFFF” module_id=”social” _builder_version=”4.24.2″ _module_preset=”default” background_color=”#e5e5e5″ bottom_divider_style=”slant2″ bottom_divider_height=”47px” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” header_2_font=”|700|||||||” header_2_text_color=”#ea5504″ global_colors_info=”{}”]

Social Media<\/h2>\n

[\/et_pb_text][et_pb_code _builder_version=”4.25.1″ _module_preset=”default” global_colors_info=”{}”]